Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on inflammatory markers (AIM) study, a substudy of ACTFAST

Luis M. Blanco-Colio, Jose L. Martín-Ventura, Eduardo De Teresa, Csaba Farsang, Allan Gaw, Gianfranco Gensini, Lawrence A. Leiter, Anatoly Langer, Pierre Martineau, Gonzalo Hérnandez, Jesús Egido

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

OBJECTIVES - Increasing evidence indicates that the Fas/Fas ligand interaction is involved in atherogenesis. We sought to analyze soluble Fas (sFas) and soluble Fas ligand (sFasL) concentrations in subjects at high cardiovascular risk and their modulation by atorvastatin treatment. METHODS AND RESULTS - ACTFAST was a 12-week, prospective, multicenter, open-label trial which enrolled subjects (statin-free or statin-treated at baseline) with coronary heart disease (CHD), CHD-equivalent, or 10-year CHD risk >20%. Subjects with LDL-C between 100 to 220 mg/dL (2.6 to 5.7 mmol/L) and triglycerides ≤600 mg/dL (6.8 mmol/L) were assigned to a starting dose of atorvastatin (10 to 80 mg/d) based on LDL-C at screening. Of the 2117 subjects enrolled in ACTFAST, AIM sub-study included the 1078 statin-free patients. At study end, 85% of these subjects reached LDL-C target. Mean sFas levels were increased and sFasL were reduced in subjects at high cardiovascular risk compared with healthy subjects. Atorvastatin reduced sFas in the whole population as well as in patients with metabolic syndrome or diabetes. Minimal changes were observed in sFasL. CONCLUSIONS - sFas concentrations are increased and sFasL are decreased in subjects at high cardiovascular risk, suggesting that these proteins may be novel markers of vascular injury. Atorvastatin reduces sFas, indicating that short-term treatment with atorvastatin exhibits antiinflammatory effects in these subjects.

Original languageEnglish
Pages (from-to)168-174
Number of pages7
JournalArteriosclerosis, thrombosis, and vascular biology
Volume27
Issue number1
DOIs
Publication statusPublished - Jan 1 2007

    Fingerprint

Keywords

  • Atorvastatin
  • C-reactive protein
  • Inflammation
  • Soluble Fas
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Blanco-Colio, L. M., Martín-Ventura, J. L., De Teresa, E., Farsang, C., Gaw, A., Gensini, G., Leiter, L. A., Langer, A., Martineau, P., Hérnandez, G., & Egido, J. (2007). Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on inflammatory markers (AIM) study, a substudy of ACTFAST. Arteriosclerosis, thrombosis, and vascular biology, 27(1), 168-174. https://doi.org/10.1161/01.ATV.0000250616.26308.d7